DelMar Pharma, Guangxi Wuzhou Establish Advisory Board in China

DelMar Pharmaceuticals, Inc. and Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. have established a clinical advisory board to oversee clinical studies aimed at expanding the market for VAL-083, known as DAG for Injection in China.
 
The companies established a collaboration and exclusive supply agreement in 2012 to help ensure the product specifications meet global standards to accelerate international development and regulatory approval for VAL-083 on a worldwide basis.
 
“Guangxi Wuzhou Pharmaceuticals is pleased to be working through the collaboration with DelMar to get VAL-083 approved by FDA and to create a foundation for sales in international markets to maximize the value of Wuzhou Pharmaceutical’s business in China. This will result in meaningful sales growth in China and international markets for the product,” said Chen Ming, vice chairman of Guangxi Wuzhou Pharmaceutical.
 
Jeffrey Bacha, president and chief executive officer of DelMar said, “Establishing a network of key opinion leaders in China is an important step in our goal to make VAL-083 available as a valuable therapy for cancer patients with limited treatment options in China and on a global basis.  Based on published literature and our own research into the mechanism of VAL-083, we believe that the drug has potential utility in a range of cancer indications.  We are very pleased to be working with Guangxi Wuzhou Pharmaceutical and this distinguished advisory board toward the successful implementation of our development and commercialization goals.”
 
VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer. DelMar is currently conducting a Phase I/II dose-escalation study in the U.S. designed to assess the safety and efficacy of VAL-083 as a potential treatment for patients suffering from refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.